Bright Minds Biosciences Inc.
DRUGHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeBright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. With a market capitalization of $864.1M, it sits in small-cap territory. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Market Cap
$864.1M
Beta
-0.19
P/E (TTM)
—
P/E (Fwd)
-10.09
EPS (TTM)
$-2.47
EPS (Fwd)
$-8.77
ROE
-15.0%
ROA
-10.4%
Cash
$309.7M
Total Debt
$82,130
Free CF
-$13.1M
52W Change
211.0%
Annual Financials
Cash vs Debt
Bright Minds Biosciences Inc. holds $309.7M in cash against $82K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$13.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -15.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Bright Minds Biosciences Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, DRUG has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DRUG.